Moderna, Inc. — MRNA
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $24.86 | $9.67B | - | -2.9 | N/A | - | - | 1.0 |
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $274.0M | $-747.0M | $-1.96 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $17.7B | $12.2B | $30.31 | 6373.0% | -1733.5% | -1646.4% |
| 2 | 2022-12-31 | $18.9B | $8.4B | $21.26 | 6.4% | -31.5% | -29.9% |
| 3 | 2023-12-31 | $6.8B | $-4.7B | $-12.33 | -64.2% | -156.4% | -158.0% |
| 4 | 2024-12-31 | $3.2B | $-3.6B | $-9.28 | -52.6% | -24.5% | -24.7% |
| 5 | TTM 2025-03-31 | $3.1B | $-3.4B | $-8.73 | -1.9% | -5.7% | -5.9% |
| 6 | Average | 1252.1% | -390.3% | -373.0% |
EPS
Forecasts
Y/Y % Change
MRNA Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 6373.0% | 6.4% | -64.2% | -52.6% | -39.7% | 31.1% | 1042.3% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 10 | 10 | |
| EPS Growth (%) | -1733.5% | -31.5% | -156.4% | -24.5% | 6.0% | -25.3% | -327.5% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 11 | 11 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $17.7B | $2.4B | $2.0B | $567.0M | $232.0M |
| 2022 | $18.9B | $5.1B | $3.3B | $1.1B | $348.0M |
| 2023 | $6.8B | $4.1B | $4.8B | $1.5B | $621.0M |
| 2024 | $3.2B | $1.3B | $4.5B | $1.2B | $189.0M |
| TTM | $3.1B | $1.3B | $3.8B | $1.1B | $208.0M |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 6.42 | 112.49 | 65.49 | 99.65 | 50.00 |
| 2023 | -64.22 | -19.65 | 47.04 | 36.84 | 78.45 |
| 2024 | -52.64 | -68.69 | -6.23 | -24.21 | -69.57 |
| TTM | -4.50 | -1.65 | -16.02 | -8.52 | 10.05 |
No unmapped expenses.
Segment Performance
SEGMENTS v2025-09-09 · 2025-09-05 15:03 UTC — Values are shown in a single scale for this table: $B. TTM values are bold. “% of Total (TTM)” shows revenue mix.
| Segment | 2022 Rev ($B) | 2022 OI ($B) | 2023 Rev ($B) | 2023 OI ($B) | 2024 Rev ($B) | 2024 OI ($B) | TTM Rev ($B) | TTM OI ($B) | % of Total (TTM) |
|---|---|---|---|---|---|---|---|---|---|
| Product Sales | 92.2B | 0.00B | 33.4B | 0.00B | 15.5B | 0.00B | 14.4B | 0.00B | 82.1% |
| C O V I D19 | 18.4B | 0.00B | 6.67B | 0.00B | 3.08B | 0.00B | 2.86B | 0.00B | 16.3% |
| Product And Service Other | 1.66B | 0.00B | 0.35B | 0.00B | 0.28B | 0.00B | 0.18B | 0.00B | 1.0% |
| Collaboration Arrangement Including Arrangements With Affiliate | 1.32B | 0.00B | 0.25B | 0.00B | 0.14B | 0.00B | 0.14B | 0.00B | 0.8% |
| Other Revenue | – | – | – | – | – | – | 0.05B | 0.00B | 0.3% |
| R S V | – | – | – | – | 0.03B | 0.00B | 0.03B | 0.00B | 0.2% |
| License And Royalty | – | – | – | – | 0.04B | 0.00B | -0.01B | 0.00B | -0.0% |
| Grant | 1.16B | 0.00B | 0.28B | 0.00B | 0.29B | 0.00B | -0.09B | 0.00B | -0.5% |
No segment data available for MRNA (axis 2).
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $12,704M |
| 1 | Cash | $1,623M |
| 2 | Total Liabilities | $2,638M |
| 3 | Total Debt | $745M |
| 4 | Total Equity | $10,066M |
| 5 | Debt to Equity Ratio | 0.07 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S |
|---|---|---|---|---|---|
| $25.90 | 4.4% | Nicks Growth: 8% Nick's Expected Margin: 10% FINVIZ Growth: 21% |
Nicks: 14 Finviz: 45 |
Nick's: 1.428 | 3.2 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $8.12 RevPS | TTM | $11.59 | -55.3% | $36.88 | 42.4% |
| $5.38 RevPS | 2025 | $7.68 | -70.3% | $24.44 | -5.6% |
| $6.72 RevPS | 2026 | $9.60 | -62.9% | $30.55 | 18.0% |
Implied Growth
No implied growth data available.